Stocks
Bio-Rad Laboratories Financial Statements (BIO) |
||||||||||
| Bio-Rad Laboratoriessmart-lab.ru | % | 2021 | 2021 | 2022 | 2022 | 2023 | LTM ? | |||
|---|---|---|---|---|---|---|---|---|---|---|
| Report date | 28.10.2021 | 11.02.2022 | 31.12.2022 | 17.02.2023 | 16.02.2024 | 16.02.2024 | ||||
| Currency | USD | USD | USD | USD | USD | USD | ||||
| Financial report URL | ||||||||||
| Revenue, bln rub | ? | 2 923 | 2 802 | 2 802 | 2 671 | 2 627 | ||||
| Operating Income, bln rub | 489.4 | 482.6 | 482.6 | 383.8 | 369.3 | |||||
| EBITDA, bln rub | ? | 650.0 | -2 375 | 664.5 | 576.2 | 532.4 | ||||
| Net profit, bln rub | ? | 4 254 | -3 628 | -3 628 | -637.3 | -600.0 | ||||
| OCF, bln rub | ? | 656.5 | 194.4 | 194.4 | 374.9 | 272.3 | ||||
| CAPEX, bln rub | ? | 120.8 | 112 782 | 114.2 | 156.7 | 121.0 | ||||
| FCF, bln rub | ? | 535.7 | 194.4 | 80.3 | 218.3 | 151.4 | ||||
| Dividend payout, bln rub | 0.000 | 68 184 | 0.000 | 0.000 | 0.000 | |||||
| Ordinary share dividend yield, % | 0.00% | 0.00% | 0.00% | 0.00% | 0.00% | 0.00% | ||||
| Dividend payout ratio, % | 0.00% | 0.00% | 0.00% | 0.00% | 0 | |||||
| OPEX, bln rub | 1 151 | 1 085 | 1 085 | 1 048 | 1 030 | |||||
| Cost of production, bln rub | 1 282 | 1 235 | 1 235 | 1 240 | 1 227 | |||||
| R&D, bln rub | 271.7 | 256.9 | 256.9 | 226.9 | 214.3 | |||||
| Interest expenses, bln rub | 1.55 | 38.1 | 38.1 | 49.4 | 49.5 | |||||
| Assets, bln rub | 19 953 | 17 776 | 13 502 | 13 502 | 12 299 | 12 299 | ||||
| Net Assets, bln rub | ? | 15 332 | 13 667 | 9 615 | 9 615 | 8 741 | 8 741 | |||
| Debt, bln rub | 12.4 | 11.0 | 1 198 | 1 198 | 1 406 | 1 406 | ||||
| Cash, bln rub | 1 343 | 875.5 | 434.2 | 1 796 | 1 613 | 1 613 | ||||
| Net debt, bln rub | -1 330 | -864.5 | 764.0 | -598.1 | -207.0 | -207.0 | ||||
| Ordinary share price, rub | 746.0 | 755.6 | 420.5 | 420.5 | 322.9 | 281.3 | ||||
| Number of ordinary shares, mln | 29.8 | 29.8 | 29.8 | 29.2 | 28.8 | |||||
| Market cap, bln rub | 0 | 22 539 | 12 524 | 12 524 | 9 431 | 8 099 | ||||
| EV, bln rub | ? | -1 330 | 21 675 | 13 288 | 11 926 | 9 224 | 7 892 | |||
| Book value, bln rub | 14 863 | 13 066 | 8 877 | 8 877 | 8 007 | 8 007 | ||||
| EPS, rub | ? | 142.6 | -121.8 | -121.8 | -21.8 | -20.8 | ||||
| FCF/share, rub | 18.0 | 6.53 | 2.70 | 7.47 | 5.26 | |||||
| BV/share, rub | 438.0 | 298.0 | 298.0 | 274.1 | 278.1 | |||||
| EBITDA margin, % | ? | 22.2% | -84.8% | 23.7% | 21.6% | 20.3% | ||||
| Net margin, % | ? | 145.6% | -129.5% | -129.5% | -23.9% | -22.8% | ||||
| FCF yield, % | ? | 0.00% | 2.38% | 1.55% | 0.64% | 2.31% | 1.87% | |||
| ROE, % | ? | 0.00% | 31.1% | -37.7% | -37.7% | -7.29% | -6.86% | |||
| ROA, % | ? | 0.00% | 23.9% | -26.9% | -26.9% | -5.18% | -4.88% | |||
| P/E | ? | 5.30 | -3.45 | -3.45 | -14.8 | -13.5 | ||||
| P/FCF | 42.1 | 64.4 | 156.0 | 43.2 | 53.5 | |||||
| P/S | ? | 7.71 | 4.47 | 4.47 | 3.53 | 3.08 | ||||
| P/BV | ? | 0.00 | 1.73 | 1.41 | 1.41 | 1.18 | 1.01 | |||
| EV/EBITDA | ? | 33.3 | -5.59 | 17.9 | 16.0 | 14.8 | ||||
| Debt/EBITDA | -1.33 | -0.32 | -0.90 | -0.36 | -0.39 | |||||
| R&D/CAPEX, % | 224.9% | 0.23% | 225.0% | 144.8% | 177.2% | |||||
| CAPEX/Revenue, % | 4.13% | 4 025% | 4.07% | 5.87% | 4.61% | |||||
| Bio-Rad Laboratories shareholders | ||||||||||
